Gamida Cell Ltd.

General Information
Business:

 

We are a clinical stage biopharmaceutical company leveraging our proprietary technology to develop cell therapies that are designed to cure cancer and rare, serious hematologic diseases. While cell therapies have the potential to address a variety of diseases, they are limited by availability of donor cells, matching a donor to the patient, and the decline in donor cell functionality when expanding the cells to achieve a therapeutic dose. We have leveraged our nicotinamide-, or NAM-, based cell expansion technology to develop a pipeline of products designed to address the limitations of cell therapies. Our proprietary technology is designed to allow for the proliferation of donor cells while maintaining the cells’ functional therapeutic characteristics, which, if approved, will provide a treatment alternative for patients.

Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Employees: 52
Founded: 1998
Contact Information
Address 5 Nahum Heftsadie St., Givaat Shaul, Jerusalem 91340, Israel
Phone Number +972 (2) 659-5666
Web Address http://www.gamida-cell.com
View Prospectus: Gamida Cell Ltd.
Financial Information
Market Cap $193.8mil
Revenues $0 mil (last 12 months)
Net Income $-30.2 mil (last 12 months)
IPO Profile
Symbol GMDA
Exchange NASDAQ
Shares (millions): 6.3
Price range $8.00 - $8.00
Est. $ Volume $50.0 mil
Manager / Joint Managers BMO Capital Markets/ RBC Capital Markets
CO-Managers Needham & Company Oppenheimer & Co.
Expected To Trade: 10/26/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change